Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

British Journal of Cancer

Volumn 81, Issue 6, 1999, Pages 1022-1030

  Brada, M ^a   Judson, I ^a   Beale, P ^a   Moore, S ^a   Reidenberg, P ^b   Statkevich, P ^c   Dugan, M ^c   Batra, V ^c   Cutler, D ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Schering Plough Research Institute ^*  (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chemotherapy; Cytotoxic; Dose escalation; Oral; Pharmacokinetics

Indexed keywords

CYTOTOXIC AGENT; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOLOGICAL AVAILABILITY; BRAIN NEOPLASMS; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FEMALE; GLIOMA; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0032728210     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690802     Document Type: Article

References (25)

1. Bleehen NM, Newlands ES, Lee SM, Thatcher LN, Selby P, Calvert AH, Rustin GJS, Brampton M and Stevens MFG (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910-913
2. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJH, Calvert H, Colquhoun I, Lewis P and Brampton MH (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484-488
3. 11C-temozolomide uptake by human recurrent high-grade astrocytomas [abstract]. Br J Cancer 75: 1241
4. Catapano CV, Broggini M, Erba E, Ponti M, Marianti L, Citti L and D'Incalci M (1987) In vitro and in vivo methazolastone-induced DNA damage and repair in L1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res 47: 4884
5. Carter CA, Waud WR and Plowman J (1994) Responses of human melanoma, ovarian, and colon tumor xenografts in nude mice to oral temozolomide. Proc Am Assoc Cancer Res 35: 297 (abstract 1769)
6. 6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 6: 389-393
7. Denny BJ, Wheelhouse RT, Stevens MFG, Tsang LLH and Slack JA (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33: 9045-9051
8. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM and Suman VJ (1997) Phase I clinical trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3: 1093-1100
9. Friedman HS, Dolan ME, Pegg AE, Marcelli S, Keir S. Catino JJ, Bigner DD and Schold SC Jr (1995) Activity of temozolomide, the treatment of central nervous system tumor xenografts. Cancer Res 55: 2853-2857
10. Kim KH, Lin CC, Parker D, Veals J, Lim J, Likhari P, Statkevich P, Marco A and Nomeir AA (1997) High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. J Chromatogr B 703: 225-233
11. 3 (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients [abstract 1370]. Proc Am Soc Clin Oncol 16: 384a.
12. Liu L, Chatterjee S and Gerson SL (1997) Blockade of base excision repair appears to mediate cytotoxicity to temozolomide in mismatch repair deficient tumor cells [abstract 1536]. Proc Am Assoc Cancer Res 38: 288
13. Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hoffman R, Stevens MFG, Brampton MH and Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287-291
14. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD and Richards PG (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A: 2236-2241.
15. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM. Illingworth RD, Richards PG, Kennard C, Colquohoun IR, Lewis P and Stevens MFG (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A: 940-942
16. Patel M, McCully C, Godwin K and Balis F (1995) Plasma and cerebrospinal fluid pharmacokineties of temozolomide [abstract 1485]. Proc Am Soc Clin Oncol 14: 461
17. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD and Grever MR (1994) Preclinical antitumor activity or temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chlorocthyl)-1 nitrosourca. Cancer Res 54: 3793-3799
18. Reidenberg P and Villalona M (1996) Phase I clinical and pharmacokinetic study of temozolomide in advanced cancer patients stratified by extent of prior therapy [abstract 344]. Ann Oncol 7: 99
19. Shen F, Decosterd LA, Gander M, Leyvraz S, Biollaz J and Lejeune FJ (1995) Determination of temozolmide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. Chromatogr B 667: 291-300
20. Stevens MFG, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Bigson NW, Slack JA, Newton C, Lunt E, Fizames C and Lavelle F (1987) Anti-tumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo (5, 1-d)- 1,2,3,5-tetrazin-4(3H)-one; a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846-5852
21. Tsang LLH, Farmer PB, Gescher A and Slack JA (1990) Characterization of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol 26: 429-436
22. Waud WR, Rubinstein LV, Kaldandrug S, Plowman J and Alley MC (1996) In vivo combination chemotherapy evaluations of topotecan with cisplatin and temozolomide [abstract 1988]. Proc Am Assoc Cancer Res 37: 292
23. 6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74: 1030-1036
24. 6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 40b: 266-272
25. Wedge SR, Portcous JK, Glaser MG, Marcus K and Newlands ES (1997b) In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8a: 92-97